BTIG raises Ceribell stock price target to $30 on growth outlook
BTIG has raised its price target for Ceribell (NASDAQ:CBLL) to $30 from $28, maintaining a Buy rating, citing the company's market leadership in point-of-care rapid EEG and recent FDA approval for pediatric and neonate expansion. A BTIG survey indicates a 30% compound annual growth rate in headband volume between 2025 and 2028, further supported by the upcoming full launch of the Ceribell Delirium Monitor and strong Q2 2026 revenue growth of 33%. Despite a wider-than-expected Q2 loss, analysts view the company's advancements in seizure detection and new products favorably.
TimesSquare Capital Management LLC Makes New $15.18 Million Investment in CeriBell, Inc. $CBLL
TimesSquare Capital Management LLC has made a new $15.18 million investment in CeriBell, Inc. (NASDAQ:CBLL), acquiring 780,552 shares. This new stake represents approximately 2.06% of CeriBell, and comes as other institutional investors have also adjusted their holdings. Despite the company missing earnings estimates in its latest quarter, analysts maintain a "Moderate Buy" rating with a $22.00 average price target, while insiders have recently sold shares but still retain a significant 17.7% ownership.
Ceribell (CBLL) CEO exercises 33K stock options in August
Ceribell, Inc. President and CEO, Xingjuan Chao, exercised stock options for a total of 33,096 common shares on August 13, 2026. This transaction involved converting derivative awards into common stock at exercise prices of $2.24 for 8,096 shares and $3.65 for 25,000 shares. The filing also notes indirect holdings of 369,088 shares through the ACP 2021 Trust, where Chao is a co-trustee, with disclaimers of beneficial ownership except for her pecuniary interest.
Don't Ignore The Insider Selling In CeriBell
An independent director at CeriBell, Joseph Taylor, recently sold US$306k worth of shares, representing 21% of his holding. While the sale occurred at the current share price, insider selling generally raises concerns, especially since no insiders have purchased shares in the last year. Despite insiders owning 5.6% of the company, this recent selling activity suggests caution for potential investors.
Ceribell director Joseph Taylor sells $306,423 in company stock
Ceribell director Joseph Michael Taylor sold 13,095 shares of the company's common stock for $306,423. This transaction comes as Ceribell shares trade near their 52-week high, with the stock returning 97% over the past year. Despite recent revenue growth, the company reported a wider-than-expected loss per share in its Q2 2026 earnings.
CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor Sells 13,095 Shares
CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor sold 13,095 shares of the company's stock for $306,423, reducing his holdings by 21.27% to 48,478 shares. This sale occurred while CeriBell's stock traded near its 12-month high, despite the company missing quarterly EPS estimates but exceeding revenue expectations. Analysts generally maintain a "Moderate Buy" rating for CBLL, with target prices ranging up to $28.
Ceribell (CBLL) director sells 13,095 shares of common stock at $23.40
Ceribell (CBLL) director Joseph Michael Taylor sold 13,095 shares of common stock at $23.40 per share on August 13, 2026, totaling $306,423. Following this transaction, Taylor directly holds 48,478 shares of Ceribell common stock. This insider sale was reported via a Form 4 filing, indicating a moderate filing impact and negative sentiment.
CeriBell (NASDAQ:CBLL) Trading Up 9.7% - Here's Why
CeriBell (NASDAQ:CBLL) saw its stock price jump by 9.7% to $23.37 following bullish analyst actions from Canaccord Genuity and BTIG Research, despite missing earnings estimates. The company, which specializes in newborn hearing screening devices, still faces unprofitability with a negative net margin, and insiders have recently sold shares, though institutional interest from firms like BlackRock has increased. The stock holds a "Moderate Buy" consensus rating with an average target of $22.00.
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell is expanding its brainwave-monitoring platform beyond seizure detection, introducing new products for delirium and pediatric patients, and eventually stroke. The company's technology offers faster, more accessible EEG monitoring in acute care settings, supported by AI-powered detection algorithms. CeriBell aims to grow its hospital customer base, increase utilization within existing accounts, and leverage new indications and reimbursement pathways to expand its total addressable market.
Ceribell Wins FDA Nod for AI Tools on Its Neurology Portal
Ceribell has received FDA 510(k) clearances for two AI enhancements integrated into its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These tools aim to improve the diagnosis of epilepsy and streamline the interpretation of EEGs by automatically highlighting abnormal brain wave patterns and reducing interference. The company hopes these advancements will help neurologists make faster, more confident decisions at the patient's bedside.
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell (NASDAQ: CBLL) is expanding its brainwave-monitoring platform beyond seizure detection to include products for delirium, pediatric patients, and eventually stroke, significantly increasing its U.S. total addressable market to over $3.5 billion. The company, which already serves 712 U.S. hospitals, is also developing new hardware and targeting multi-hospital health-system deals to further penetrate the market. Despite ongoing litigation with Natus, CeriBell is investing in future growth and product launches rather than focusing on near-term operating leverage.
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell is expanding its brainwave-monitoring platform beyond seizure detection to include new products for delirium, pediatric patients, and eventually stroke, aiming to make EEG monitoring faster and more accessible in acute care settings. The company is increasing its hospital customer base, maturing its sales force, and has secured favorable Medicare reimbursement for its delirium-detection product. CeriBell estimates these new applications will increase its U.S. total addressable market to over $3.5 billion.
CeriBell (CBLL) Stock Premium Rides High Margins Despite Deeper Losses
CeriBell (CBLL) stock saw a 10.4% increase after its Q2 earnings report, driven by headline growth in its high-margin medical device business, despite widened net losses. The company reported revenue of US$28.1m and a net loss of US$19.3m, with investors crediting progress in hospital penetration and product pipeline. Despite the premium 8x price-to-sales multiple compared to peers, concerns remain regarding increased operating expenses and execution risks for future revenue drivers.
CeriBell (NASDAQ:CBLL) Receives "Buy" Rating from BTIG Research
BTIG Research has reaffirmed its "Buy" rating for CeriBell (NASDAQ:CBLL) and maintained a $28 price target, indicating a potential 45% upside from its current price of $19.30. Despite a wider-than-expected Q2 loss of $0.51 per share, the company's revenue exceeded estimates at $28.1 million. Institutional interest in CeriBell has grown, with new positions from major investors, though insider selling presents a potential headwind.
Canaccord raises Ceribell stock price target on strong Q2 results
Canaccord increased its price target for Ceribell (NASDAQ:CBLL) to $26 from $25, maintaining a Buy rating, following strong Q2 fiscal 2026 results. The company reported $28.1 million in revenue, a 33% year-over-year increase, and raised its full-year revenue guidance to $114 million-$117 million. Despite the positive outlook and impressive gross margins, InvestingPro analysis suggests the stock might be overvalued.
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) reported a Q2 loss of $0.51 per share, missing the Zacks Consensus Estimate of a $0.45 loss, but exceeded revenue estimates with $28.1 million. Despite underperforming the S&P 500 this year, the company's revenue has topped consensus estimates four times in the last four quarters. Investors are advised to watch management's commentary and earnings estimate revisions, with the stock currently holding a Zacks Rank #3 (Hold).
CeriBell Lifts 2026 Revenue Forecast on AI EEG Growth, Reports Wider Quarterly Loss
Ceribell has raised its 2026 revenue forecast to $114-$117 million after a 33% increase in Q2 sales, driven by new hospital accounts and higher utilization. Despite strong growth, the GAAP net loss widened by 41% to $19.3 million due to operating expenses rising faster than revenue. Investors are focusing on account growth to achieve operating leverage and the impact of a one-off tariff refund on the reported 92% gross margin.
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
Ceribell, Inc. announced FDA 510(k) clearance for two new AI algorithm enhancements for its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These enhancements aim to improve the precision and efficiency of critical-care EEG review by filtering complex background interference and streamlining the interpretation of lengthy brain recordings. The technology is designed to help neurologists make faster, more confident bedside decisions by highlighting epileptiform patterns and isolating non-cerebral artifacts.
CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ...
CeriBell Inc (CBLL) reported a significant revenue increase of 33% year-over-year to $28.1 million in Q2 2026, driven by strong product and subscription growth. Despite widening net losses due to increased operating expenses and IP litigation costs, the company achieved a record gross margin and secured FDA clearances for new algorithms and a New Technology Add-on Payment for its Delirium Monitoring Solution. CeriBell raised its full-year 2026 revenue guidance, projecting continued growth from new product launches and strategic account expansion, with profitability expected in the longer term.
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) reported a Q2 loss of $0.51 per share, missing the Zacks Consensus Estimate of a $0.45 loss, but exceeded revenue expectations with $28.1 million against an estimated $27.22 million. Despite the revenue beat, the company's shares have fallen 14.2% year-to-date, contrasting with the S&P 500's 13.3% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating an expected performance in line with the market.
Ceribell forecasts FY 2026 revenue of $114 million-$117 million
Ceribell has issued a revenue guidance for FY 2026, projecting $114 million-$117 million. The company reported a 33% year-over-year revenue increase in Q2 2026 and a year-to-date gross margin of 90% as of June 30, 2026. Ceribell estimates a U.S. market opportunity of $3.5 billion, including a $400 million expansion into pediatric and neonate indications which began commercial launch in Q1 2026.
Earnings call transcript: Ceribell tops revenue growth in Q2 2026, shares rise
Ceribell reported strong Q2 2026 results, with revenue growing 33% year-over-year to $28.1 million, surpassing expectations despite an EPS miss. The medical-device company's shares rose as investors focused on its continued expansion in seizure detection, record gross margins of 92%, and advancement of new products for delirium monitoring and pediatric care. Ceribell also raised its full-year 2026 revenue guidance to $114 million to $117 million, driven by core business momentum and new FDA clearances.
Ceribell Reports Second Quarter 2026 Financial Results
Ceribell announced strong second-quarter 2026 financial results, with total revenue increasing 33% to $28.1 million driven by new account additions and increased utilization. The company also reported significant milestones, including multiple FDA 510(k) clearances for new algorithms and hardware designs, a new credit facility, and a New Technology Add-On Payment (NTAP) for its delirium monitoring solution. Ceribell raised its full-year 2026 revenue guidance to $114 million to $117 million, reflecting continued business momentum.
Ceribell Receives FDA 510(k) Clearance for New AI-Driven Neurology Portal Enhancements to Improve EEG Interpretation
Ceribell announced it received FDA 510(k) clearance for AI algorithm enhancements to its Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These new features aim to improve EEG interpretation in critical-care settings by filtering out interference and highlighting abnormalities. The enhancements were developed based on clinical feedback and are designed to integrate seamlessly into existing workflows, helping neurologists make faster, more confident diagnoses.
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
Ceribell has received FDA 510(k) clearance for two new AI algorithm enhancements for its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These enhancements aim to improve the precision of critical-care EEG review by filtering complex background interference and streamlining the interpretation of lengthy brain recordings. The technology helps neurologists make faster, more confident bedside decisions by highlighting epileptiform patterns and isolating non-cerebral artifacts.
What To Expect From CeriBell Inc (CBLL) Q2 2026 Earnings
CeriBell Inc (CBLL) is scheduled to release its Q2 2026 earnings on August 10, 2026, with revenue expected at $27.29 million and an estimated earnings per share of -$0.47. Analysts project full-year 2026 revenue to be $113.98 million and earnings per share to be -$1.71, with the stock currently having an average "Buy" recommendation and an implied upside of 47.32% from its current price based on analyst price targets. In Q1 2026, CeriBell Inc beat revenue expectations but missed earnings estimates, leading to a 16.5% stock decline.
Ceribell Insider Sold Shares Worth $714,480, According to a Recent SEC Filing
Xingjuan Chao, Director, President, and CEO of Ceribell (CBLL), sold 39,000 shares of the company on August 3, 2026. This transaction amounted to a total value of $714,480. The sale was disclosed in a recent SEC filing.
Ceribell CEO Xingjuan Chao disposes of 39,000 common shares for $714,480
Ceribell President and CEO Xingjuan Chao sold 39,000 common shares for $714,480 at a weighted average of $18.32 per share on August 3. Concurrently, she acquired 25,000 common shares through option exercises priced at $4.70. Following these transactions, her directly held common stock decreased to 788,317 shares, with an additional 369,088 shares held indirectly via the ACP 2021 Trust.
Ceribell, Inc. (CBLL) CEO trades 39,000 shares under 10b5-1 plan
Ceribell, Inc.'s President and CEO, Chao Xingjuan, exercised stock options for 25,000 shares at $4.70 per share and subsequently sold 39,000 common shares at a weighted average price of $18.32. These transactions, which generated approximately $714,000 in gross proceeds, were conducted under a Rule 10b5-1 trading plan. After these transactions, she directly holds 788,317 common shares and indirectly holds 369,088 shares through the ACP 2021 Trust.
Analysts’ Top NA Picks: SpaceX (SPCX), Ceribell, Inc. (CBLL)
This article highlights bullish sentiments from analysts for SpaceX (SPCX) and Ceribell, Inc. (CBLL) in the NA sector. Deutsche Bank analyst Edison Yu maintained a Buy rating for SpaceX with a $255.00 price target, while William Blair analyst Brandon Vazquez maintained a Buy rating for Ceribell, Inc. The consensus among analysts suggests a Moderate Buy for SpaceX with significant upside potential and a Strong Buy for Ceribell, Inc.
Ceribell Secures CMS New Technology Add-On Payment (NTAP)
Ceribell, a medical technology company, announced it has secured a New Technology Add-on Payment (NTAP) from the U.S. Centers for Medicare & Medicaid Services (CMS) for its Delirium Monitor System. This NTAP, providing up to $2,171 per eligible Medicare patient, aims to broaden access to the first FDA-cleared device for aiding in delirium screening and monitoring. The system, which also integrates seizure monitoring, will receive the add-on payment starting October 1, 2026, enhancing comprehensive neurological care for critically ill patients.
Ceribell’s Delirium Monitoring System Earns CMS NTAP
Ceribell has received a New Technology Add-on Payment (NTAP) from CMS for its Delirium Monitoring System, which will provide up to $2,171 per eligible Medicare case. This follows FDA 510(k) clearance for the system, which is the first and only FDA-cleared device to aid in delirium screening and monitoring. The NTAP is set to take effect on October 1, aiming to facilitate widespread access to this technology for critically ill patients.
Ceribell Receives CMS NTAP for Delirium Monitoring System, Expanding Medicare Access for Point-of-Care EEG Platform
Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has approved a New Technology Add-on Payment (NTAP) of up to $2,171 for eligible Medicare patients using their FDA-cleared Delirium Monitor System. This system is the first of its kind for delirium screening and monitoring through continuous EEG analysis, integrating both seizure and delirium monitoring into a single point-of-care platform. The NTAP, effective October 1, 2026, aims to expand access to this technology for critically ill patients and supports Ceribell's mission to establish EEG as a vital sign in healthcare.
CeriBell stock rises after securing Medicare payment approval By Investing.com
CeriBell Inc. (NASDAQ:CBLL) shares rose 3% after receiving Medicare payment approval for its Delirium Monitor System. The New Technology Add-on Payment (NTAP) will provide up to $2,171 per eligible Medicare patient, effective October 1, 2026. This approval follows the FDA 510(k) clearance of the system in December 2025, marking it as the first and only FDA-cleared device for delirium screening and monitoring.
One Ceribell System Tracks Both Seizures and Delirium at Bedside
Ceribell (Nasdaq: CBLL) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case for its Delirium Monitor System, effective October 1, 2026. This system is the first and only FDA-cleared device to aid in delirium screening and monitoring, building on Ceribell's existing point-of-care EEG technology for nonconvulsive seizures. The unified platform now allows for simultaneous monitoring of both seizures and delirium in critically ill patients using a single bedside system.
Form 4 CeriBell Inc For: 30 July By Investing.com
This article from Investing.com announces the filing of Form 4 for CeriBell Inc. on July 30. It includes the stock symbol CBLL and notes a 0.28% change. The content primarily serves as a placeholder announcement, offering no further details on the Form 4 itself.
Ceribell, Inc. (CBLL) director receives 16,011 RSUs grant
Ceribell, Inc. director Sharon O'Keefe was granted 16,011 restricted stock units (RSUs) on July 28, 2026. This award, valued at $0.00 per unit, brought her total direct holdings to 16,011 RSUs. The transaction, reported in a Form 4 filing, indicates an equity award rather than an open-market purchase, consistent with RSU grants.
Form 4 CeriBell Inc For: 30 July By Investing.com
This article reports on a Form 4 filing for CeriBell Inc. dated July 30. It is a brief announcement without further details on the content of the filing. The article also includes various market data and other news headlines.
Ceribell (CBLL) director receives 16,011 restricted stock units in equity award
Ceribell, Inc. director Thomas A. West was granted 16,011 restricted stock units (RSUs) of Common Stock on July 28, 2026, as reported in a Form 4 filing. This equity award, valued at $0.00 per share, establishes his direct ownership at 16,011 shares. RSUs are a compensation-related acquisition that vests over time and are not an open-market purchase.
Ceribell files Form 3 initial beneficial ownership statement for director Sharon O’Keefe
Ceribell has filed an initial Form 3 beneficial ownership statement for its director, Sharon O’Keefe, dated July 28. This information was generated using AI by Public Technologies (PUBT) from original content published by Ceribell Inc. via the SEC's EDGAR system.
CeriBell (NASDAQ: CBLL) expands board to nine, adds O’Keefe and West
CeriBell, Inc. (NASDAQ: CBLL) has expanded its Board of Directors from seven to nine members, effective July 28, 2026, and rebalanced its director classes for more equal representation. Sharon L. O’Keefe and Thomas A. West were elected as new Class I directors, with O'Keefe joining the Compensation Committee and West joining the Audit Committee. Both new non-employee directors will receive annual cash compensation, restricted stock units, and an initial RSU award valued at $300,000, vesting over three years.
Ceribell appoints Thomas West and Sharon O’Keefe to its Board to boost brain monitoring tech adoption.
Ceribell, a medical technology company focused on neurological care, has appointed Thomas West and Sharon O’Keefe to its Board of Directors. These strategic appointments aim to accelerate the commercial scaling and adoption of Ceribell’s point-of-care brain monitoring platform within hospitals. The company's FDA-cleared AI-powered EEG technology is currently used in over 680 U.S. hospitals for rapid diagnosis and continuous monitoring of neurological conditions.
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company focusing on neurological conditions, has appointed Thomas West and Sharon O’Keefe to its Board of Directors. West brings extensive experience in scaling medical technologies and leading acquisitions, while O’Keefe offers vast leadership experience from major academic health systems. These appointments aim to strengthen Ceribell's commercial adoption and market leadership as its point-of-care brain monitoring platform expands.
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company, has appointed Thomas West and Sharon O’Keefe to its Board of Directors to help expand the adoption of its point-of-care brain monitoring platform. West brings extensive experience in scaling medical technologies, including leadership roles at Nalu Medical and Intersect ENT, while O’Keefe offers deep insights from leading major academic health systems like the University of Chicago Medical Center. Their combined expertise is expected to be invaluable as Ceribell aims to solidify its leadership in brain monitoring and enhance patient care for serious neurological conditions.
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
Ceribell, Inc. (Nasdaq: CBLL), a medical technology company, announced that its CFO, Scott Blumberg, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Wednesday, August 12, 2026, at 6:00 a.m. PDT / 9:00 a.m. EDT. A webcast of the presentation will be available on the company's investor relations website.
CeriBell Inc (CBLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of CeriBell Inc (CBLL), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. It highlights that CBLL's current price momentum score is 4.39, ranking it within the top half of its industry, and notes its suitability for range-bound swing trading with a resistance at $20.20 and support at $15.71. The analysis also summarizes buy, sell, and neutral signals from multiple indicators and moving averages, concluding with a "Neutral" overall signal based on technical analysis.
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West brings experience scaling medical technologies and led companies through significant acquisitions, while O’Keefe offers extensive leadership experience from major academic health systems. Their combined expertise is expected to be invaluable as Ceribell expands its point-of-care brain monitoring platform, currently deployed in over 680 U.S. hospitals.
CeriBell Inc (CBLL) Financial Health: Profitability & Balance Sheet Analysis
CeriBell Inc (CBLL) currently holds a robust financial score of 7.30, placing it 93rd out of 199 companies in the Healthcare Equipment & Supplies industry. The company reported a 29.30% year-over-year increase in quarterly revenue to $26.49M, and a significant 54.47% increase in net profit. Despite its strong financial status, its operating efficiency is noted as low, with several detailed financial metrics yet to be disclosed.
Ceribell CFO to speak at Canaccord Genuity Growth Conference on Aug 12, 2026
Ceribell, a medical technology company focusing on neurological diagnostics, announced that its CFO, Scott Blumberg, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. This event, highlighting Ceribell's portable AI-powered EEG system, signifies the company's continuous engagement with investors and the medical technology community. The conference will be held in Boston and will be livestreamed on Ceribell's investor relations website.
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
Ceribell, Inc. (Nasdaq: CBLL), a medical technology company specializing in neurological conditions, announced that its CFO, Scott Blumberg, will present at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026, at 9:00 a.m. EDT, and will be livestreamed. Ceribell focuses on transforming the diagnosis and management of serious neurological conditions with its FDA-cleared Ceribell System, an EEG platform for acute-care settings.
